Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | KEYNOTE-224: pembrolizumab monotherapy for previously untreated HCC

Jean-Luc Van Laethem • 20 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Liver Cancer Antibodies Pembrolizumab
KEYNOTE-224

Jean-Luc Van Laethem, MD, PhD, Erasme Hospital University, Brussels, Belgium, discusses the results of the KEYNOTE-224 study (NCT02702414), a Phase II trial evaluating pembrolizumab monotherapy for previously untreated hepatocellular carcinoma (HCC). Checkpoint blockade in these patients demonstrated durable anti-tumor activity, promising overall survival, and no new associated safety signals. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Jean-Luc Van Laethem

3:05
Highlights in HCC from ASCO GI 2021
Jean-Luc Van Laethem • 20 Jan 2021
4:16
Challenges in using immuno-oncology for GI malignancies
Jean-Luc Van Laethem • 20 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals